Ashleigh Palmer, Provention Bio CEO
September 1, 2022 10:41 AM EDTUpdated 10:55 AM
Financing

Proven­tion Bio takes a $125M loan to ad­vance Eli Lil­ly’s once-re­ject­ed di­a­betes drug

Aayushi Pratap

News Reporter

Amidst the on­go­ing biotech mar­ket slow­down, com­pa­nies are try­ing var­i­ous ways to stay afloat. Some are go­ing pub­lic, and some are tak­ing on debt. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times